The Report of Global Antibody Drug Conjugate Market by Market Research Future Covers the Information like Global Antibody Drug Conjugate Market Growth Global Antibody Drug Conjugate Market: By Types (Monoclonal Antibodies, Linker), Product (Adcertis, Kadcyla) Technology (Immunogen Technology, Immunomedics Technology), Applications (Leukemia, Lymphoma) End-Users (Biotechnology Companies) – Forecast 2023
Competitive Dashboard: Antibody Drug Conjugate Market
Some of the key players profiled by MRFR are Seattle Genetics (U.S.), ImmunoGen, Inc. (U.S.), Roche Holding AG (Switzerland), Antikor (U.K.), Immunomedics (U.S.), Pfizer Inc. (U.S.), Celldex Therapeutics (U.S.), Millennium Pharmaceuticals (U.S.), AbbVie Inc. (U.S.), Genentech (U.S.), Concortis Biotherapeutics (U.S.), Agensys, Inc. (U.S.), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (U.S.), Heidelberg Pharma (Germany), Oxford BioTherapeutics (U.S.), Mersana Therapeutics (U.S.), and Synthon (U.S.).
Market Insights: Antibody Drug Conjugate Market
Market Research Future (MRFR) Has Estimated In Its Latest Report That The Global Antibody Drug Conjugate Market Is Set To Proliferate Saliently At A CAGR Of 19% During The Forecast Period 2017 To 2023. These drug conjugates are regarded as the new age of therapeutic agents. The efficiency of the drug in treating diseases has propelled demand in the global market, and the trend is likely to perpetuate over the next few years.
Antibody drug conjugates (ADCs) are a new class of biopharmaceutical drug containing an antibody with to a biologically active drug. They are designed to eliminate the tumor after being released in the bloodstream to target cancerous cells. The global antibody drug conjugate market report by Market Research Future (MRFR) contains in detail the effects of ADCs as well as the large potential in medical applications.
The effects of targeting specific cells coupled with the killing ability of cytotoxic drugs make this antibody drug conjugate the ideal choice for the treatment of various cancers. The rising prevalence of cancer all across the globe has catapulted the antibody drug conjugate market on an upward trajectory. Additionally, the advancements in medical technologies are anticipated to drive the growth of the global market by enhancing the accuracy of the drug.
Increased investments in research & developments in the antibody drug conjugate market are further expected to augment the market size. Nevertheless, the high cost associated with the procedures is likely to hold the market growth through the projection period.
Fill Out Details To Receive FREE Sample Here: https://www.marketresearchfuture.com/sample_request/1113
Industry Developments: Antibody Drug Conjugate Market
In July 2018, Daiichi Sankyo Company, Limited and Glycotope GmbH have inked a pact regarding the combination of Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab and Daiichi Sankyo’s proprietary ADC technology for developing gatipotuzumab antibody drug conjugate
There are many factors that is fueling the growth of the antibody drug conjugate market. The different market trends and factors in this market according to an analysis performed by Market Research Future (MRFR) include increasing prevalence of cancer, advancement in medical technology, increased investment in R & D, efficacy of ADC in treating diseases, rising collaboration amid biotechnology and biopharmaceuticals and research institutes, preclinical research, growing geriatric population and rise in obese population. On the contrary, the soaring cost related to the procedure may hamper the growth of the antibody drug conjugate market.
Drivers and Restraints: Antibody Drug Conjugate Market
The market is about to witness a rise in demand for ADCs owing to the prevalence of chronic diseases such as cancer. With the rising population, the number of people affected by the disease is also on the rise. ADCs offer a better fighting chance against the disease, and by giving a faster recovery time, it reinstalls hope in patients. This has also given rise to the demand for ADCs. Also, the advances in linker technology have widened the scope of ADC improvisation. Efforts towards patent protection can provide the ADC market a boost and a robust shape.
However, ADCs incur heavy cost as the production has both upstream and downstream hurdles that affect the feasibility. Moreover, the lack of experienced hands and regulatory challenges can prove as impediments for the market during the forecast period.
Market Segmentation: Antibody Drug Conjugate Market
By type, the global antibody drug conjugate market is segmented into monoclonal antibodies, linker, drug/toxin, and others.
By application, the antibody drug conjugate market has been segmented into leukemia, prostate cancer, kidney cancer, pancreas cancer, ovary cancer, glioblastoma, lung cancer, colon cancer, breast cancer, skin cancer, solid tumors, multiple myeloma, lymphoma, and other cancers. The leukemia segment is further sub-segmented into Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), and Chronic Lymphocytic Leukemia (CLL).
By product, the global antibody drug conjugate market is segmented into Adcertis, Kadcyla, and others.
By technology, the antibody drug conjugate market has been segmented into ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others.
By end-user, the global antibody drug conjugate market is segmented into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, biopharmaceutical companies, and others.
Regional Analysis: Antibody Drug Conjugate Market
By region, the global antibody drug conjugate market is segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas dominate the global market owing to technological innovations, manufacturing process advancements, the contribution of nanotechnology, etc. Led by the U.S., the region is anticipated to retain its pole position through the assessment period. Europe is likely to retain its second spot trailed by the Asia Pacific which is an emerging market for antibody drug conjugate.
Table Of Content: Antibody Drug Conjugate Market
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Antibody Drug Conjugate Market, By Type
6.1 Introduction
6.2 Monoclonal Antibodies
6.2.1 Market Estimates & Forecast, 2017–2023
6.3 Linker
6.3.1 Market Estimates & Forecast, 2017–2023
6.4 Drug/Toxin
6.4.1 Market Estimates & Forecast, 2017–2023
6.5 Others
Chapter 7. Global Antibody Drug Conjugate Market, By Application
7.1 Introduction
7.2 Leukemia
7.2.1 Market Estimates & Forecast, 2017–2023
7.2.2 Acute Myeloid Leukemia (AML)
7.2.2.1 Market Estimates & Forecast, 2017–2023
7.2.3 Chronic Myeloid Leukemia (CML)
7.2.3.1 Market Estimates & Forecast, 2017–2023
7.2.4 Acute Lymphocytic Leukemia (ALL)
7.2.4.1 Market Estimates & Forecast, 2017–2023
7.2.5 Chronic Lymphocytic Leukemia (CLL)
7.2.5.1 Market Estimates & Forecast, 2017–2023
7.3 Prostate Cancer
7.3.1 Market Estimates & Forecast, 2017–2023
7.4 Kidney Cancer
7.4.1 Market Estimates & Forecast, 2017–2023
7.5 Pancreas Cancer
7.5.1 Market Estimates & Forecast, 2017–2023
7.6 Ovary Cancer
7.6.1 Market Estimates & Forecast, 2017–2023
7.7 Glioblastoma
7.7.1 Market Estimates & Forecast, 2017–2023
7.8 Lung Cancer
7.8.1 Market Estimates & Forecast, 2017–2023
7.9 Colon Cancer
7.9.1 Market Estimates & Forecast, 2017–2023
7.10 Breast Cancer
7.10.1 Market Estimates & Forecast, 2017–2023
7.11 Skin Cancer
7.11.1 Market Estimates & Forecast, 2017–2023
7.12 Solid Tumors
7.12.1 Market Estimates & Forecast, 2017–2023
7.13 Multiple Myeloma
7.13.1 Market Estimates & Forecast, 2017–2023
7.14 Lymphoma
7.14.1 Market Estimates & Forecast, 2017–2023
7.15 Others
Chapter 8. Global Antibody Drug Conjugate Market, By Product
8.1 Introduction
8.2 Adcertis
8.2.1 Market Estimates & Forecast, 2017–2023
8.3 Kadcyla
8.3.1 Market Estimates & Forecast, 2017–2023
8.4 Others
Chapter 9. Global Antibody Drug Conjugate Market, By Technology
9.1 Introduction
9.2 ImmunoGen Technology
9.2.1 Market Estimates & Forecast, 2017–2023
9.3 Seattle Genetics Technology
9.3.1 Market Estimates & Forecast, 2017–2023
9.4 Immunomedics Technology
9.4.1 Market Estimates & Forecast, 2017–2023
9.4 Others…..
LIST OF TABLES
Table 1 Antibody Drug Conjugate Industry Synopsis, 2017–2023
Table 2 Antibody Drug Conjugate Market Estimates & Forecast, 2017–2023, (USD Million)
Table 3 Antibody Drug Conjugate Market, By Region, 2017–2023, (USD Million)
Table 4 Antibody Drug Conjugate Market, By Type, 2017–2023, (USD Million)
Table 5 Antibody Drug Conjugate Market, By Application, 2017–2023, (USD Million)
Table 6 Antibody Drug Conjugate Market, By Product, 2017–2023, (USD Million)
Table 7 Antibody Drug Conjugate Market, By Technology, 2017–2023, (USD Million)
Table 8 Antibody Drug Conjugate Market, By End-User, 2017–2023, (USD Million)
Table 9 North America Antibody Drug Conjugate Market, By Type, 2017–2023, (USD Million)
Table 10 North America Antibody Drug Conjugate Market, By Application, 2017–2023, (USD Million) others…..
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation For Antibody Drug Conjugate Market
Figure 3 Segmentation Market Dynamics For Antibody Drug Conjugate Market
Figure 4 Global Antibody Drug Conjugate Market Share, By Type, 2016
Figure 5 Global Antibody Drug Conjugate Market Share, By Application, 2016
Figure 6 Global Antibody Drug Conjugate Market Share, By Product, 2016
Figure 8 Global Antibody Drug Conjugate Market Share, By Technology, 2016
Figure 9 Global Antibody Drug Conjugate Market Share, By End-User, 2016
Figure 10 Global Antibody Drug Conjugate Market Share, By Region, 2016
Figure 11 North America Antibody Drug Conjugate Market Share, By Country, 2016
Figure 12 Europe Antibody Drug Conjugate Market Share, By Country, 2016
Figure 13 Asia Pacific Antibody Drug Conjugate Market Share, By Country, 2016
Figure 14 The Middle East & Africa Antibody Drug Conjugate Market Share, By Country, 2016
Figure 15 Global Antibody Drug Conjugate Market: Company Share Analysis, 2016 (%)
Figure 16 Seattle Genetics: Key Financials
Figure 17 Seattle Genetics: Segmental Revenue
Figure 18 Seattle Genetics: Geographical Revenue
Figure 19 ImmunoGen, Inc.: Key Financials
Figure 20 ImmunoGen, Inc.: Segmental Revenue
Figure 21 ImmunoGen, Inc.: Geographical Revenue
Figure 22 Roche Holding AG: Key Financials
Figure 23 Roche Holding AG: Segmental Revenue
Figure 24 Roche Holding AG: Geographical Revenue
Figure 25 Genentech: Key Financials
Continued…
Get Complete Report Details with Detail Tables and Figures @ https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com